The U.S. Food and Drug Administration (FDA) would like drug makers to submit the results of genomic tests when seeking approval for new drugs. But pharmaceutical companies often don’t know what kind of information to submit or whether revealing the results of genomic tests will help or hurt their chances of getting a new drug approved.
